{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T10:35:12Z","timestamp":1789900512142,"version":"4.0.1"},"reference-count":68,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Sexual Medicine Reviews"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.sxmr.2018.03.008","type":"journal-article","created":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T06:09:51Z","timestamp":1530166191000},"page":"583-594","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Cardiovascular Safety of Phosphodiesterase Type 5 Inhibitors After Nearly 2 Decades on the Market"],"prefix":"10.1093","volume":"6","author":[{"given":"Robert A.","family":"Kloner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irwin","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Sadovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"10.1016\/j.sxmr.2018.03.008_bib1","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ucl.2005.08.007","article-title":"Physiology of penile erection and pathophysiology of erectile dysfunction","volume":"32","author":"Dean","year":"2005","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.sxmr.2018.03.008_bib2","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrd893","article-title":"Phosphodiesterase 5 inhibitors: current status and potential applications","volume":"1","author":"Rotella","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.sxmr.2018.03.008_bib3","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.amjcard.2013.02.009","article-title":"Sexual function in patients with chronic angina pectoris","volume":"111","author":"Kloner","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.sxmr.2018.03.008_bib4","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1093\/cvr\/cvp170","article-title":"Phosphodiesterase 5 inhibitors: are they cardioprotective?","volume":"83","author":"Reffelmann","year":"2009","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.sxmr.2018.03.008_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0002-9149(99)00042-9","article-title":"Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in\u00a0vitro","volume":"83","author":"Wallis","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.sxmr.2018.03.008_bib6","first-page":"407","article-title":"Phosphodiesterase-5 (PDE5) inhibitors in the management of erectile dysfunction","volume":"38","author":"Huang","year":"2013","journal-title":"P\u00a0T"},{"key":"10.1016\/j.sxmr.2018.03.008_bib7","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1161\/CIRCULATIONAHA.110.944603","article-title":"Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension","volume":"122","author":"Schwartz","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.sxmr.2018.03.008_bib8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/thoraxjnl-2015-207170","article-title":"The molecular targets of approved treatments for pulmonary arterial hypertension","volume":"71","author":"Humbert","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.sxmr.2018.03.008_bib9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4103\/2141-9248.183943","article-title":"The wonders of phosphodiesterase-5 inhibitors: a majestic history","volume":"6","author":"Elhwuegi","year":"2016","journal-title":"Ann Med Health Sci Res"},{"key":"10.1016\/j.sxmr.2018.03.008_bib10","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1742-1241.2009.02254.x","article-title":"Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database","volume":"64","author":"Giuliano","year":"2010","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.sxmr.2018.03.008_bib11","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1742-1241.2007.01679.x","article-title":"Cardiovascular outcomes among sildenafil users: results of the International Men\u2019s Health study","volume":"62","author":"Mittleman","year":"2008","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.sxmr.2018.03.008_bib12","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1742-1241.2003.tb10566.x","article-title":"Clinical trials of sildenafil citrate (Viagra) demonstrate no increase in risk of myocardial infarction and cardiovascular death compared with placebo","volume":"57","author":"Mittleman","year":"2003","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.sxmr.2018.03.008_bib13","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.amjcard.2005.12.073","article-title":"Cardiovascular safety update of tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of tadalafil with as-needed, three times-per-week or once-a-day dosing","volume":"97","author":"Kloner","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.sxmr.2018.03.008_bib14","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1464-410X.2007.06581.x","article-title":"An observational cohort study investigating the cardiovascular safety of tadalafil when prescribed in primary care in England: mortality due to ischemic heart disease","volume":"99","author":"Hazell","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2018.03.008_bib15","doi-asserted-by":"crossref","first-page":"858715","DOI":"10.1155\/2014\/858715","article-title":"The SIAMS-ED trial: a national, independent, multicenter study on cardiometabolic and hormonal impairment of men with erectile dysfunction treated with vardenafil","volume":"2014","author":"Isidori","year":"2014","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.sxmr.2018.03.008_bib16","first-page":"3161","article-title":"The Real-Life Safety and Efficacy of vardenafil (REALISE) study: results in men from Europe and overseas with erectile dysfunction and cardiovascular or metabolic conditions","volume":"7","author":"Van Ahlen","year":"2010","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2018.03.008_bib17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.urology.2006.05.047","article-title":"Cardiovascular safety of sildenafil citrate (Viagra\u00ae): an updated perspective","volume":"68","author":"Jackson","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.sxmr.2018.03.008_bib18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0002-9149(99)00045-4","article-title":"Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease","volume":"83","author":"Conti","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.sxmr.2018.03.008_bib19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1742-1241.2001.tb11009.x","article-title":"Swedish Sildenafil Investigators Group. Efficacy and safety of sildenafil citrate for the treatment of erectile dysfunction in men with cardiovascular disease","volume":"55","author":"Olsson","year":"2001","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.sxmr.2018.03.008_bib20","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0090-4295(02)01752-1","article-title":"A\u00a04-year update on the safety of sildenafil citrate (Viagra)","volume":"60","author":"Padma-Nathan","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.sxmr.2018.03.008_bib21","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.amjcard.2005.03.097","article-title":"Evaluation of acute risk for myocardial infarction in men treated with sildenafil citrate","volume":"96","author":"Mittleman","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.sxmr.2018.03.008_bib22","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/iju.12699","article-title":"Tadalafil 5 mg once daily for the treatment of Asian men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: analyses of data pooled from three randomized, double-blind, placebo-controlled studies","volume":"22","author":"Nishizawa","year":"2015","journal-title":"Int J Urol"},{"key":"10.1016\/j.sxmr.2018.03.008_bib23","doi-asserted-by":"crossref","first-page":"647","DOI":"10.4111\/kju.2010.51.9.647","article-title":"Efficacy and safety of tadalafil 5 mg administered once daily in Korean men with erectile dysfunction: a prospective, multicenter study","volume":"51","author":"Kang","year":"2010","journal-title":"Korean J Urol"},{"key":"10.1016\/j.sxmr.2018.03.008_bib24","doi-asserted-by":"crossref","first-page":"e85805","DOI":"10.1371\/journal.pone.0085805","article-title":"Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men","volume":"9","author":"Finkle","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.sxmr.2018.03.008_bib25","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1111\/j.1742-1241.2008.01852.x","article-title":"Global experiences with vardenafil in men with erectile dysfunction and underlying conditions","volume":"62","author":"Eardley","year":"2008","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.sxmr.2018.03.008_bib26","first-page":"265","article-title":"10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors","volume":"9","author":"Lowe","year":"2012","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2018.03.008_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00129784-200808010-00001","article-title":"Does sildenafil cause myocardial infarction or sudden cardiac death?","volume":"8","author":"Kontaras","year":"2008","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.sxmr.2018.03.008_bib28","doi-asserted-by":"crossref","first-page":"1424.e1","DOI":"10.1016\/j.ajem.2013.05.019","article-title":"The relationship between acute coronary syndrome and sildenafil","volume":"31","author":"Ekinozu","year":"2013","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.sxmr.2018.03.008_bib29","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000100397","article-title":"Acute myocardial infarction following sildenafil intake in a nitrate-free patient without previous history of coronary artery disease","volume":"16","author":"Hayat","year":"2007","journal-title":"Med Princ Pract"},{"key":"10.1016\/j.sxmr.2018.03.008_bib30","first-page":"s35","article-title":"An unusual adverse effect of sildenafil citrate: acute myocardial infarction in a nitrate free patient [abstract]","volume":"155","author":"Cakmak","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.sxmr.2018.03.008_bib31","first-page":"325","article-title":"Sildenafil citrate and torsade de pointes","volume":"99","author":"Falcon-Chevere","year":"2007","journal-title":"Bol Asoc Med P R"},{"key":"10.1016\/j.sxmr.2018.03.008_bib32","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/01.ccm.0000475072.56552.e1","article-title":"OTC sexual enhancement and poppers: a deadly combination unknown to the public [abstract]","volume":"43","author":"Foster","year":"2015","journal-title":"Crit Care Med"},{"key":"10.1016\/j.sxmr.2018.03.008_bib34","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(14)60887-4","article-title":"Poppers maculopathy","volume":"384","author":"Gruener","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.sxmr.2018.03.008_bib35","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1161\/01.CIR.99.1.168","article-title":"Use of sildenafil (Viagra) in patients with cardiovascular disease. ACC\/AHA Expert Consensus Document","volume":"99","author":"Cheitlin","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.sxmr.2018.03.008_bib36","first-page":"e30","article-title":"Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases","volume":"16","author":"Kukreja","year":"2011","journal-title":"Exp Clin Cardiol"},{"key":"10.1016\/j.sxmr.2018.03.008_bib37","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/FJC.0b013e318291be81","article-title":"The safety of preoperative vardenafil in patients undergoing coronary artery bypass graft surgery","volume":"62","author":"Ali","year":"2013","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.sxmr.2018.03.008_bib38","doi-asserted-by":"crossref","first-page":"LB650","DOI":"10.1096\/fasebj.28.1_supplement.lb650","article-title":"Administration of sildenafil at reperfusion fails to reduce infarct size: results from the CAESAR Cardioprotection Consortium [abstract]","volume":"28","author":"Kukreja","year":"2014","journal-title":"FASEB J"},{"key":"10.1016\/j.sxmr.2018.03.008_bib39","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1365-2044.2011.06702.x","article-title":"Pre-operative sildenafil and pulmonary endothelial-related complications following cardiopulmonary bypass: a randomized trial in children undergoing cardiac surgery","volume":"66","author":"Vassalos","year":"2011","journal-title":"Anaesthesia"},{"key":"10.1016\/j.sxmr.2018.03.008_bib40","first-page":"238","article-title":"Sildenafil therapy for pulmonary hypertension before and after pediatric congenital heart surgery","volume":"38","author":"Palma","year":"2011","journal-title":"Tex Heart Inst J"},{"key":"10.1016\/j.sxmr.2018.03.008_bib41","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00246-009-9632-x","article-title":"Postoperative use of oral sildenafil in pediatric patients with congenital heart disease","volume":"31","author":"Uhm","year":"2010","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.sxmr.2018.03.008_bib42","doi-asserted-by":"crossref","first-page":"H32","DOI":"10.1016\/S1520-765X(02)90050-7","article-title":"Overview of the cardiovascular effects of tadalafil","volume":"4","author":"Emmick","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1016\/j.sxmr.2018.03.008_bib43","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1097\/00004872-200018120-00022","article-title":"Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication. Sildenafil Study Group","volume":"18","author":"Zusman","year":"2000","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.sxmr.2018.03.008_bib44","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3233\/CH-2008-1096","article-title":"Sublingual application of liquid nitrendipine does not result in critical hypotension in healthy volunteers under phosphodiesterase-5 inhibition","volume":"39","author":"Park","year":"2008","journal-title":"Clin Hemorheol Microcirc"},{"key":"10.1016\/j.sxmr.2018.03.008_bib45","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1742-1241.2006.00817.x","article-title":"Ivabradine\u2014the first selective sinus node I(f) channel inhibitor in the treatment of stable angina","volume":"60","author":"Sulfi","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.sxmr.2018.03.008_bib46","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/01.RES.86.5.580","article-title":"The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid\u00a0oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase","volume":"86","author":"Kantor","year":"2000","journal-title":"Circ Res"},{"key":"10.1016\/j.sxmr.2018.03.008_bib47","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1161\/CIR.0b013e3182776f83","volume":"126","author":"Fihn","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.sxmr.2018.03.008_bib48","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1524-6175.2005.05285.x","article-title":"The effect of antihypertensive drugs on erectile function: a proposed management algorithm","volume":"8","author":"Doumas","year":"2006","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.sxmr.2018.03.008_bib49","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.291.3.309","article-title":"Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial","volume":"291","author":"Chaitman","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.sxmr.2018.03.008_bib50","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jacc.2003.11.045","article-title":"Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina","volume":"43","author":"Chaitman","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.sxmr.2018.03.008_bib51","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejphar.2006.05.016","article-title":"Ranolazine, a novel anti-anginal agent, does not alter isosorbide dinitrate- or sildenafil-induced changes in blood pressure in conscious dogs","volume":"541","author":"Zhao","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.sxmr.2018.03.008_bib52","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1097\/01.CCM.0000269371.70738.30","article-title":"Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: a double-blind, placebo-controlled, randomized, crossover trial","volume":"35","author":"Parker","year":"2007","journal-title":"Crit Care Med"},{"key":"10.1016\/j.sxmr.2018.03.008_bib53","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1161\/HYPERTENSIONAHA.109.147686","article-title":"Clinical potential of combined organic nitrate and phosphodiesterase type 5 inhibitor in treatment-resistant hypertension","volume":"56","author":"Oliver","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.sxmr.2018.03.008_bib54","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cardfail.2008.09.005","article-title":"Combined use of PDE5 inhibitors and nitrates in the treatment of pulmonary arterial hypertension in patients with heart failure","volume":"15","author":"Stehlik","year":"2009","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.sxmr.2018.03.008_bib55","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/ijcp.12779","article-title":"Serum testosterone, testosterone replacement therapy and all-cause mortality in men with type 2 diabetes: retrospective consideration of the impact of PDE5 inhibitors and statins","volume":"70","author":"Hackett","year":"2016","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.sxmr.2018.03.008_bib56","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/smrj.36","article-title":"Testosterone and cardiovascular health: safety of treatment of hypogonadism","volume":"3","author":"Kloner","year":"2015","journal-title":"Sex Med Rev"},{"key":"10.1016\/j.sxmr.2018.03.008_bib57","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.sxmr.2017.02.002","article-title":"The Graham Jackson Memorial Lecture ISSM 2016\u2014\"the man who knew too much\": time to recognize erectile dysfunction and low testosterone as independent risk factors for cardiovascular disease","volume":"5","author":"Hackett","year":"2017","journal-title":"Sex Med Rev"},{"key":"10.1016\/j.sxmr.2018.03.008_bib58","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eururo.2004.10.002","article-title":"Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk","volume":"47","author":"Rosano","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2018.03.008_bib59","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.jacc.2007.10.069","article-title":"Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors","volume":"51","author":"Gazzaruso","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.sxmr.2018.03.008_bib60","doi-asserted-by":"crossref","first-page":"H888","DOI":"10.1152\/ajpheart.00215.2014","article-title":"Repeated daily dosing with sildenafil provides sustained protection from endothelial dysfunction caused by ischemia and reperfusion: a human in\u00a0vivo study","volume":"307","author":"McLaughlin","year":"2014","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.sxmr.2018.03.008_bib61","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0008-6363(03)00435-8","article-title":"Effects of sildenafil on myocardial infarct size, microvascular function, and acute ischemic left ventricular dilation","volume":"59","author":"Reffelmann","year":"2003","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.sxmr.2018.03.008_bib62","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1161\/CIRCULATIONAHA.106.626226","article-title":"Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure","volume":"115","author":"Lewis","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.sxmr.2018.03.008_bib63","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12916-014-0185-3","article-title":"Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials","volume":"12","author":"Giannetta","year":"2014","journal-title":"BMC Med"},{"key":"10.1016\/j.sxmr.2018.03.008_bib64","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.jacc.2007.07.078","article-title":"Long-term use of sildenafil in the therapeutic management of heart failure","volume":"50","author":"Guazzi","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.sxmr.2018.03.008_bib65","first-page":"887","article-title":"Coronary heart disease, diabetes, and sexuality in men","volume":"13","author":"Hackett","year":"2016","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2018.03.008_bib66","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1136\/heartjnl-2015-309223","article-title":"Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality","volume":"102","author":"Anderson","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.sxmr.2018.03.008_bib67","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4239\/wjd.v8.i3.104","article-title":"Statin, testosterone and phosphodiesterase 5-inhibitor treatments and age-related mortality in diabetes","volume":"8","author":"Hackett","year":"2017","journal-title":"World J Diabetes"},{"key":"10.1016\/j.sxmr.2018.03.008_bib68","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1136\/heartjnl-2016-310746","article-title":"Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction","volume":"103","author":"Andersson","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.sxmr.2018.03.008_bib69","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1161\/CIRCHEARTFAILURE.112.969071","article-title":"Phosphodiesterase-5 inhibition to improve clinical status and exercise capacity in diastolic heart failure (RELAX) trial: rationale and design","volume":"5","author":"Redfield","year":"2012","journal-title":"Circ Heart Fail"}],"container-title":["Sexual Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2050052118300532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2050052118300532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T11:29:16Z","timestamp":1693740556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2050052118300532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":68,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S2050052118300532"],"URL":"https:\/\/doi.org\/10.1016\/j.sxmr.2018.03.008","relation":{},"ISSN":["2050-0521"],"issn-type":[{"value":"2050-0521","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular Safety of Phosphodiesterase Type 5 Inhibitors After Nearly 2 Decades on the Market","name":"articletitle","label":"Article Title"},{"value":"Sexual Medicine Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sxmr.2018.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}